TriClip™ TEER

Quickly Return to Better Lives
with Better Health1

For Millions with TR, a state of the art Treatment has Emerged1

TriClip™ Transcatheter Edge to Edge Repair (TEER) is a non-surgical alternative treatment for Tricuspid Regurgitation (TR) that offers a sustained reduction of TR with significant improvements in clinical outcomes and proven safety

  • Patients with severe symptomatic TR that are high surgical risk
  • Patients who are not seeing improvement from medical therapy alone

PATIENTS WITH SEVERE TRICUSPID REGURGITATION HAVE SIGNIFICANTLY IMPAIRED QUALITY OF LIFE

  • Shortness of breath
  • Peripheral edema
  • Ascites
  • Fatigue
  • Declining exercise capacity

Current Treatment Options Have Limitations

For many patients with TR, medical management is not enough

Medical management for TR has little impact on survival2
 

Most patients receive medical management until right heart failure or end-organ dysfunction appears 3

Retrospective analysis of 13,026 patients with HFrEF Stage B or C with EF < 50%. Exclusions criteria included previous valve surgery, PPML and moderate or severe organic, mitral or aortic valve disease.2

Surgery is High Risk and Often Denied3,4

Surgery for TR is seldom performed. Factors prohibiting surgery include:

  • High operative risk (8%–13% operative mortality)
  • Multiple comorbidities
  • Advanced age
  • Lack of effectiveness

MAT-2006557 v4.0 | Item approved for Global OUS use only.

References
  1. Lurz P, et al. Trasncatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol. 2021;77:229-23
  2. Benfari G, Antoine C, Mille WL, Thapa P, Topilsky Y, Rossi A, Michelena HI, Pislaru S, Enriquez-Sarano M. Excess Mortality Associate with Functional Tricuspid Regurgitation Complicating Heart Failure with Reduced Ejection Fraction. Circ. 2019;16;140(3):196-206
  3. Enriquez-Sarano M, Messika-Zeitnoun D, Topilsky Y, et al. Tricuspid regurgitation is a public health crisis [published online ahead of print November 9, 2019]. Prog Cardiovasc Dis. November-December 2019;62(6):447-451. Doi:10.1016/j.pcad.2019.10.009.
  4. Moraca et al. Outcomes of Tricuspid Valve Repair and Replacement: A Propensity Analysis. Ann Thorac Surg 2009;87:83–9.

Sign up

Receive updates from Abbott Structural Heart

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

YOU ARE ABOUT TO LEAVE
www.structural­heart­solutions.com

You are now leaving www.structuralheartsolutions.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.